Temozolomide in patients with a glioblastoma multiforme: New developments;Temozolomide bij patiënten met een glioblastoma multiforme: Nieuwe ontwikkelingen

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 25, 2005, Pages 1376-1378

  Bromberg, J E C ^a   Postma, T J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

CANCER ADJUVANT THERAPY; DRUG EFFICACY; DRUG INDICATION; GENE; GLIOBLASTOMA; HUMAN; METHYLATION; MGMT GENE; PROMOTER REGION; REVIEW; SURVIVAL RATE; TUMOR RECURRENCE; ADJUVANT CHEMOTHERAPY; BRAIN TUMOR; MORTALITY; NOTE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 20944433817     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Stupp R, Mason WP, Bent MJ van den, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups. National Cancer Institute of Canada Clinical Trials Group. N Engl J Med 2005; 352:987-96.
2. Taphoorn MJB, Stupp R, Osoba D, Curschmann J, Kortmann R, Bent MJ van den, et al. An international phase III, randomised, controlled trial evaluating health-related quality of life in glioblastoma patients [abstract]. Neuro-Oncol 2004;6:358(A).
3. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit of temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
4. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
5. Taal W, Rijt CDD van der, Sillevis Smitt PAE, Kros JM, Heuvel I van, Enting RH, et al. Gunstig resultaat van temozolomide bij een recidief van een hooggradig glioom. Ned Tijdschr Geneeskd 2005;149: 1393-9.
6. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572-8.